Key result
Contemporary and novel therapeutics, including SGLT2 inhibitors, mineralocorticoid receptor antagonists, and emerging drug categories, offer promising approaches to retard chronic kidney disease progression.
Why the study?
Chronic kidney disease has a rising incidence, high morbidity, and serious cardiovascular complications, warranting novel therapeutic approaches to prevent its development or slow progression.
A narrative review summarizing novel and emerging therapeutic approaches, including SGLT2 inhibitors and non-steroidal MRAs, to manage chronic kidney disease and its cardiovascular complications.
Chronic kidney disease (CKD) remains a pathologic entity with constantly rising incidence and high rates of morbidity and mortality, which are associated with serious cardiovascular complications. Moreover, the incidence of end-stage renal disease tends to increase. The epidemiological trends of CKD warrant the development of novel therapeutic approaches aiming to prevent its development or retard its progression through the control of major risk factors: type 2 diabetes mellitus, arterial hypertension, and dyslipidemia. Contemporary therapeutics such as sodium-glucose cotransporter-2 inhibitors and second-generation mineralocorticoid receptor antagonists are utilized in this direction. Additionally, experimental and clinical studies present novel drug categories that could be employed in managing CKD, such as aldosterone synthesis inhibitors or activators guanylate cyclase, while the role of melatonin should be further tested in the clinical setting. Finally, in this patient population, the use of hypolipidemic agents may provide incremental benefits.
No takes yet. Share an insight, caveat, or question.
Theofilis et al. (2023) conducted a review in Chronic kidney disease. Novel therapeutic approaches (SGLT2 inhibitors, MRAs, aldosterone synthesis inhibitors, guanylate cyclase activators) was evaluated. Contemporary and novel therapeutics, including SGLT2 inhibitors, mineralocorticoid receptor antagonists, and emerging drug categories, offer promising approaches to retard chronic kidney disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: